Related Experiment Videos
MIB-1 assessments in breast cancers
S Iqbal1, T J Anderson, L P Marson
1Edinburgh Breast Unit, Western General Hospital, UK.
Breast (Edinburgh, Scotland)
|February 18, 2004
Summary
MIB-1 measurements in breast cancer biopsies show significant variability between individual samples, despite no average difference. This heterogeneity limits the utility of MIB-1 for monitoring treatment response in individual patients.
Area of Science:
- Oncology
- Pathology
- Biostatistics
Background:
- Proliferation markers like MIB-1 are crucial in breast cancer assessment.
- Accurate and consistent MIB-1 measurements are needed for treatment monitoring.
Purpose of the Study:
- To assess the variability of MIB-1 measurements between core and excision biopsies in breast cancer.
- To determine if MIB-1 measurements are equivalent for individual patients.
Main Methods:
- Histological sections from core and excision biopsies were analyzed.
- Biopsies were taken simultaneously and sequentially (2-3 weeks apart).
- MIB-1 scores were compared between paired samples.
Main Results:
- No significant average difference in MIB-1 scores between core and excision biopsies.
- Substantial differences observed in individual pairs of cores and sections.
- Wide 95% confidence intervals for MIB-1 ratios within individuals (0.14-6.68).
Conclusions:
- While MIB-1 measurements may be equivalent on average across many patients, they are not equivalent within individuals.
- Severe tumor heterogeneity complicates MIB-1 assessment in individual breast cancers.
- The utility of MIB-1 for monitoring treatment-induced proliferation changes in individual patients is limited.